View Older Stories View More Recent Stories

Oct 23, 2024 07:05AM Ionis to hold third quarter 2024 financial results webcast
Oct 21, 2024 05:57AM Ionis Pharmaceuticals (IONS) reports WAINZUA recommended for approval in the EU by CHMP
Oct 21, 2024 02:08AM WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
Oct 3, 2024 07:01AM Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at ACAAI
Oct 3, 2024 07:00AM New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Oct 1, 2024 07:01AM Ionis Pharmaceuticals (IONS): Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Oct 1, 2024 07:00AM Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Sep 4, 2024 08:00AM Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Aug 28, 2024 07:05AM Ionis to present at upcoming investor conferences
Aug 1, 2024 07:00AM Ionis reports second quarter 2024 financial results
Jul 22, 2024 07:03AM Ionis Pharmaceuticals (IONS) announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Jul 22, 2024 07:00AM Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Jul 19, 2024 08:24AM Ionis to hold second quarter 2024 financial results webcast
Jul 18, 2024 07:00AM Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
Jul 8, 2024 07:05AM Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
Jun 25, 2024 06:55AM Ionis Pharmaceuticals (IONS) announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Jun 25, 2024 06:55AM Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Jun 18, 2024 07:04AM Ionis Pharmaceuticals (IONS) expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Jun 18, 2024 07:00AM Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Jun 17, 2024 04:09PM Ionis to present at TD Cowen Genetic Medicines & RNA Summit
May 31, 2024 07:02AM Ionis (IONS) presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
May 31, 2024 07:00AM Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
May 28, 2024 07:00AM Ionis to hold donidalorsen Phase 3 data webcast
May 23, 2024 07:00AM New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
May 16, 2024 07:31AM Biogen (BIIB) and Ionis (IONS) Report Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024 07:30AM Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024 07:30AM Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024 07:03AM Ionis Pharmaceuticals (IONS) Reports Positive Results from Phase 1/2a trial of ION582
May 16, 2024 07:00AM Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
May 15, 2024 07:05AM Ionis to host 2024 virtual Annual Meeting of Stockholders
May 7, 2024 07:00AM Ionis reports first quarter 2024 financial results
Apr 25, 2024 07:00AM Ionis Publishes 2023 Corporate Responsibility Report
Apr 23, 2024 07:05AM Ionis to hold first quarter 2024 financial results webcast
Apr 7, 2024 09:48AM Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Apr 1, 2024 07:05AM Ionis to present at upcoming investor conferences
Mar 28, 2024 07:05AM Ionis to hold olezarsen Phase 3 data webcast
Mar 25, 2024 08:19AM Ionis Pharmaceuticals (IONS) to Present Positive Phase 3 Balance Data
Mar 25, 2024 08:18AM Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Mar 13, 2024 07:01AM Ionis Pharmaceuticals (IONS) Reports Positive Results from Phase 2 Study of ION224
Mar 13, 2024 07:00AM Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Feb 29, 2024 09:06AM Ionis Pharmaceuticals (IONS) Appoints Kyle Jenne as Chief Global Product Strategy Officer
Feb 29, 2024 09:05AM Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Feb 28, 2024 07:05AM Ionis to present at upcoming investor conferences
Feb 21, 2024 07:00AM Ionis reports fourth quarter and full year 2023 financial results
Feb 15, 2024 07:01AM Ionis Pharmaceuticals (IONS) Granted FDA Orphan Drug designation for Olezarsen
Feb 15, 2024 07:00AM Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Feb 8, 2024 07:04AM Ionis Pharmaceuticals (IONS) Granted FDA Fast Track Designation for Eplontersen
Feb 8, 2024 07:00AM Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Feb 7, 2024 07:05AM Ionis to hold fourth quarter and full year 2023 financial results webcast
Jan 22, 2024 07:01AM Ionis Pharmaceuticals (IONS) Reports Positive Topline Results from Phase 3 OASIS-HAE Study
View More Recent Stories View Older Stories